1
|
Zhao Z, Zhu J, Zhou L, Sun N, Chang K, Hu X, Hu Y, Ren M, Cheng Y, Xu D, Xin H, Zhang C. Establishment of a hydrodynamic delivery system in ducks. Transgenic Res 2024; 33:35-46. [PMID: 38461212 DOI: 10.1007/s11248-024-00377-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Accepted: 02/20/2024] [Indexed: 03/11/2024]
Abstract
Chronic hepatitis B virus (HBV) poses a significant global health challenge as it can lead to acute or chronic liver disease and hepatocellular carcinoma (HCC). To establish a safety experimental model, a homolog of HBV-duck HBV (DHBV) is often used for HBV research. Hydrodynamic-based gene delivery (HGD) is an efficient method to introduce exogenous genes into the liver, making it suitable for basic research. In this study, a duck HGD system was first constructed by injecting the reporter plasmid pLIVE-SEAP via the ankle vein. The highest expression of SEAP occurred when ducks were injected with 5 µg/mL plasmid pLIVE-SEAP in 10% bodyweight volume of physiological saline for 6 s. To verify the distribution and expression of exogenous genes in multiple tissues, the relative level of foreign gene DNA and β-galactosidase staining of LacZ were evaluated, which showed the plasmids and their products were located mainly in the liver. Additionally, β-galactosidase staining and fluorescence imaging indicated the delivered exogenous genes could be expressed in a short time. Further, the application of the duck HGD model on DHBV treatment was investigated by transferring representative anti-HBV genes IFNα and IFNγ into DHBV-infected ducks. Delivery of plasmids expressing IFNα and IFNγ inhibited DHBV infection and we established a novel efficient HGD method in ducks, which could be useful for drug screening of new genes, mRNAs and proteins for anti-HBV treatment.
Collapse
Affiliation(s)
- Zhanji Zhao
- Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Jiabing Zhu
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Lijian Zhou
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Nan Sun
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Kaile Chang
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Xiaoyue Hu
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
- Institute of Translational Medicine, Jiangxi Medical College,, Nanchang University, Nanchang, 330031, People's Republic of China
| | - Yuting Hu
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
- Institute of Translational Medicine, Jiangxi Medical College,, Nanchang University, Nanchang, 330031, People's Republic of China
| | - Mingzhi Ren
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Yan Cheng
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Derong Xu
- Institute of Translational Medicine, Jiangxi Medical College,, Nanchang University, Nanchang, 330031, People's Republic of China
| | - Hongbo Xin
- Institute of Translational Medicine, Jiangxi Medical College,, Nanchang University, Nanchang, 330031, People's Republic of China
| | - Chunbo Zhang
- Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China.
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China.
- Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Ministry of Education, Jiangxi Medical College, Nanchang University, Nanchang, 330031, People's Republic of China.
| |
Collapse
|
2
|
Baselga M, Uranga-Murillo I, de Miguel D, Arias M, Sebastián V, Pardo J, Arruebo M. Silver Nanoparticles–Polyethyleneimine-Based Coatings with Antiviral Activity against SARS-CoV-2: A New Method to Functionalize Filtration Media. MATERIALS 2022; 15:ma15144742. [PMID: 35888208 PMCID: PMC9318907 DOI: 10.3390/ma15144742] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Revised: 06/27/2022] [Accepted: 07/04/2022] [Indexed: 02/06/2023]
Abstract
The use of face masks and air purification systems has been key to curbing the transmission of SARS-CoV-2 aerosols in the context of the current COVID-19 pandemic. However, some masks or air conditioning filtration systems are designed to remove large airborne particles or bacteria from the air, being limited their effectiveness against SARS-CoV-2. Continuous research has been aimed at improving the performance of filter materials through nanotechnology. This article presents a new low-cost method based on electrostatic forces and coordination complex formation to generate antiviral coatings on filter materials using silver nanoparticles and polyethyleneimine. Initially, the AgNPs synthesis procedure was optimized until reaching a particle size of 6.2 ± 2.6 nm, promoting a fast ionic silver release due to its reduced size, obtaining a stable colloid over time and having reduced size polydispersity. The stability of the binding of the AgNPs to the fibers was corroborated using polypropylene, polyester-viscose, and polypropylene-glass spunbond mats as substrates, obtaining very low amounts of detached AgNPs in all cases. Under simulated operational conditions, a material loss less than 1% of nanostructured silver was measured. SEM micrographs demonstrated high silver distribution homogeneity on the polymer fibers. The antiviral coatings were tested against SARS-CoV-2, obtaining inactivation yields greater than 99.9%. We believe our results will be beneficial in the fight against the current COVID-19 pandemic and in controlling other infectious airborne pathogens.
Collapse
Affiliation(s)
- Marta Baselga
- Institute for Health Research Aragon (IIS Aragón), 50009 Zaragoza, Spain; (I.U.-M.); (D.d.M.); (M.A.); (V.S.); (J.P.); (M.A.)
- Correspondence:
| | - Iratxe Uranga-Murillo
- Institute for Health Research Aragon (IIS Aragón), 50009 Zaragoza, Spain; (I.U.-M.); (D.d.M.); (M.A.); (V.S.); (J.P.); (M.A.)
- Department of Microbiology, Pediatrics, Radiology and Public Health, Facultad de Medicina, University of Zaragoza, 50009 Zaragoza, Spain
- Networking Research Center on Infectious Diseases, CIBERINFEC, 28029 Madrid, Spain
| | - Diego de Miguel
- Institute for Health Research Aragon (IIS Aragón), 50009 Zaragoza, Spain; (I.U.-M.); (D.d.M.); (M.A.); (V.S.); (J.P.); (M.A.)
- Department of Microbiology, Pediatrics, Radiology and Public Health, Facultad de Medicina, University of Zaragoza, 50009 Zaragoza, Spain
| | - Maykel Arias
- Institute for Health Research Aragon (IIS Aragón), 50009 Zaragoza, Spain; (I.U.-M.); (D.d.M.); (M.A.); (V.S.); (J.P.); (M.A.)
- Department of Microbiology, Pediatrics, Radiology and Public Health, Facultad de Medicina, University of Zaragoza, 50009 Zaragoza, Spain
- Networking Research Center on Infectious Diseases, CIBERINFEC, 28029 Madrid, Spain
| | - Victor Sebastián
- Institute for Health Research Aragon (IIS Aragón), 50009 Zaragoza, Spain; (I.U.-M.); (D.d.M.); (M.A.); (V.S.); (J.P.); (M.A.)
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain
- Department of Chemical Engineering, Campus Río Ebro–Edificio I+D, University of Zaragoza, 50018 Zaragoza, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, 28029 Madrid, Spain
| | - Julián Pardo
- Institute for Health Research Aragon (IIS Aragón), 50009 Zaragoza, Spain; (I.U.-M.); (D.d.M.); (M.A.); (V.S.); (J.P.); (M.A.)
- Department of Microbiology, Pediatrics, Radiology and Public Health, Facultad de Medicina, University of Zaragoza, 50009 Zaragoza, Spain
- Networking Research Center on Infectious Diseases, CIBERINFEC, 28029 Madrid, Spain
| | - Manuel Arruebo
- Institute for Health Research Aragon (IIS Aragón), 50009 Zaragoza, Spain; (I.U.-M.); (D.d.M.); (M.A.); (V.S.); (J.P.); (M.A.)
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain
- Department of Chemical Engineering, Campus Río Ebro–Edificio I+D, University of Zaragoza, 50018 Zaragoza, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, 28029 Madrid, Spain
| |
Collapse
|
3
|
Developments in Cell-Penetrating Peptides as Antiviral Agents and as Vehicles for Delivery of Peptide Nucleic Acid Targeting Hepadnaviral Replication Pathway. Biomolecules 2018; 8:biom8030055. [PMID: 30013006 PMCID: PMC6165058 DOI: 10.3390/biom8030055] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Revised: 07/10/2018] [Accepted: 07/11/2018] [Indexed: 12/11/2022] Open
Abstract
Alternative therapeutic approaches against chronic hepatitis B virus (HBV) infection need to be urgently developed because current therapies are only virostatic. In this context, cell penetration peptides (CPPs) and their Peptide Nucleic Acids (PNAs) cargoes appear as a promising novel class of biologically active compounds. In this review we summarize different in vitro and in vivo studies, exploring the potential of CPPs as vehicles for intracellular delivery of PNAs targeting hepadnaviral replication. Thus, studies conducted in the duck HBV (DHBV) infection model showed that conjugation of (D-Arg)8 CPP to PNA targeting viral epsilon (ε) were able to efficiently inhibit viral replication in vivo following intravenous administration to ducklings. Unexpectedly, some CPPs, (D-Arg)8 and Decanoyl-(D-Arg)8, alone displayed potent antiviral effect, altering late stages of DHBV and HBV morphogenesis. Such antiviral effects of CPPs may affect the sequence-specificity of CPP-PNA conjugates. By contrast, PNA conjugated to (D-Lys)4 inhibited hepadnaviral replication without compromising sequence specificity. Interestingly, Lactose-modified CPP mediated the delivery of anti-HBV PNA to human hepatoma cells HepaRG, thus improving its antiviral activity. In light of these promising data, we believe that future studies will open new perspectives for translation of CPPs and CPP-PNA based technology to therapy of chronic hepatitis B.
Collapse
|
4
|
Abstract
With high morbidity and mortality worldwide, there is great interest in effective therapies for chronic hepatitis B (CHB) virus. There are currently several dozen investigational agents being developed for treatment of CHB. They can be broadly divided into two categories: (1) direct-acting antivirals (DAAs) that interfere with a specific step in viral replication; and (2) host-targeting agents that inhibit viral replication by modifying host cell function, with the latter group further divided into the subcategories of immune modulators and agents that target other host functions. Included among the DAAs being developed are RNA interference therapies, covalently closed circular DNA (cccDNA) formation and transcription inhibitors, core/capsid inhibitors, reverse transcriptase inhibitors, hepatitis B surface antigen (HBsAg) release inhibitors, antisense oligonucleotides, and helioxanthin analogues. Included among the host-targeting agents are entry inhibitors, cyclophilin inhibitors, and multiple immunomodulatory agents, including Toll-like receptor agonists, immune checkpoint inhibitors, therapeutic vaccines, engineered T cells, and several cytokine agents, including recombinant human interleukin-7 (CYT107) and SB 9200, a novel therapy that is believed to both have direct antiviral properties and to induce endogenous interferon. In this review we discuss agents that are currently in the clinical stage of development for CHB treatment as well as strategies and agents currently at the evaluation and discovery phase and potential future targets. Effective approaches to CHB may require suppression of viral replication combined with one or more host-targeting agents. Some of the recent research advances have led to the hope that with such a combined approach we may have a functional cure for CHB in the not distant future.
Collapse
Affiliation(s)
- Altaf Dawood
- Department of Internal Medicine, Section of Gastroenterology, University of Nevada School of Medicine, Las Vegas, NV, USA
| | - Syed Abdul Basit
- Department of Internal Medicine, Section of Gastroenterology, University of Nevada School of Medicine, Las Vegas, NV, USA
| | - Mahendran Jayaraj
- Department of Internal Medicine, Section of Gastroenterology, University of Nevada School of Medicine, Las Vegas, NV, USA
| | - Robert G Gish
- Department of Internal Medicine, Section of Gastroenterology, University of Nevada School of Medicine, Las Vegas, NV, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA.
- Hepatitis B Foundation, Doylestown, PA, USA.
- Asian Pacific Health Foundation, San Diego, CA, USA.
- National Viral Hepatitis Roundtable, Washington, DC, USA.
| |
Collapse
|
5
|
Role of Cell-Penetrating Peptides in Intracellular Delivery of Peptide Nucleic Acids Targeting Hepadnaviral Replication. MOLECULAR THERAPY. NUCLEIC ACIDS 2017; 9:162-169. [PMID: 29246295 PMCID: PMC5633256 DOI: 10.1016/j.omtn.2017.09.003] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Revised: 09/07/2017] [Accepted: 09/07/2017] [Indexed: 02/08/2023]
Abstract
Peptide nucleic acids (PNAs) are potentially attractive antisense agents against hepatitis B virus (HBV), although poor cellular uptake limits their therapeutic application. In the duck HBV (DHBV) model, we evaluated different cell-penetrating peptides (CPPs) for delivery to hepatocytes of a PNA-targeting hepadnaviral encapsidation signal (ε). This anti-ε PNA exhibited sequence-specific inhibition of DHBV RT in a cell-free system. Investigation of the best in vivo route of delivery of PNA conjugated to (D-Arg)8 (P1) showed that intraperitoneal injection to ducklings was ineffective, whereas intravenously (i.v.) injected fluorescein-P1-PNA reached the hepatocytes. Treatment of virus carriers with i.v.-administered P1-PNA resulted in a decrease in viral DNA compared to untreated controls. Surprisingly, a similar inhibition of viral replication was observed in vivo as well as in vitro in primary hepatocyte cultures for a control 2 nt mismatched PNA conjugated to P1. By contrast, the same PNA coupled to (D-Lys)4 (P2) inhibited DHBV replication in a sequence-specific manner. Interestingly, only P1, but not P2, displayed anti-DHBV activity in the absence of PNA cargo. Hence, we provide new evidence that CPP-PNA conjugates inhibit DHBV replication following low-dose administration. Importantly, our results demonstrate the key role of CPPs used as vehicles in antiviral specificity of CPP-PNA conjugates.
Collapse
|
6
|
Ndeboko B, Lemamy GJ, Nielsen PE, Cova L. Therapeutic Potential of Cell Penetrating Peptides (CPPs) and Cationic Polymers for Chronic Hepatitis B. Int J Mol Sci 2015; 16:28230-41. [PMID: 26633356 PMCID: PMC4691041 DOI: 10.3390/ijms161226094] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Revised: 11/17/2015] [Accepted: 11/20/2015] [Indexed: 02/06/2023] Open
Abstract
Chronic hepatitis B virus (HBV) infection remains a major health problem worldwide. Because current anti-HBV treatments are only virostatic, there is an urgent need for development of alternative antiviral approaches. In this context, cell-penetrating peptides (CPPs) and cationic polymers, such as chitosan (CS), appear of particular interest as nonviral vectors due to their capacity to facilitate cellular delivery of bioactive cargoes including peptide nucleic acids (PNAs) or DNA vaccines. We have investigated the ability of a PNA conjugated to different CPPs to inhibit the replication of duck hepatitis B virus (DHBV), a reference model for human HBV infection. The in vivo administration of PNA-CPP conjugates to neonatal ducklings showed that they reached the liver and inhibited DHBV replication. Interestingly, our results indicated also that a modified CPP (CatLip) alone, in the absence of its PNA cargo, was able to drastically inhibit late stages of DHBV replication. In the mouse model, conjugation of HBV DNA vaccine to modified CS (Man-CS-Phe) improved cellular and humoral responses to plasmid-encoded antigen. Moreover, other systems for gene delivery were investigated including CPP-modified CS and cationic nanoparticles. The results showed that these nonviral vectors considerably increased plasmid DNA uptake and expression. Collectively promising results obtained in preclinical studies suggest the usefulness of these safe delivery systems for the development of novel therapeutics against chronic hepatitis B.
Collapse
Affiliation(s)
- Bénédicte Ndeboko
- Institut National de la Sante et Recherche Medicale (INSERM) U1052, Cancer Research Center of Lyon (CRCL), Lyon 69003, France.
- Département de Biologie Cellulaire and Moléculaire-Génétique, Faculté de Médecine, Université des Sciences de la Santé, Libreville 241, Gabon.
| | - Guy Joseph Lemamy
- Département de Biologie Cellulaire and Moléculaire-Génétique, Faculté de Médecine, Université des Sciences de la Santé, Libreville 241, Gabon.
| | - Peter E Nielsen
- Department of Cellular and Molecular Medicine, Departement of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, the Panum Institute, University of Copenhagen, Copenhagen DK 2200N, Denmark.
| | - Lucyna Cova
- Institut National de la Sante et Recherche Medicale (INSERM) U1052, Cancer Research Center of Lyon (CRCL), Lyon 69003, France.
| |
Collapse
|
7
|
Progress and Prospects of Anti-HBV Gene Therapy Development. Int J Mol Sci 2015; 16:17589-610. [PMID: 26263978 PMCID: PMC4581210 DOI: 10.3390/ijms160817589] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Revised: 07/20/2015] [Accepted: 07/22/2015] [Indexed: 12/11/2022] Open
Abstract
Despite the availability of an effective vaccine against hepatitis B virus (HBV), chronic infection with the virus remains a major global health concern. Current drugs against HBV infection are limited by emergence of resistance and rarely achieve complete viral clearance. This has prompted vigorous research on developing better drugs against chronic HBV infection. Advances in understanding the life cycle of HBV and improvements in gene-disabling technologies have been impressive. This has led to development of better HBV infection models and discovery of new drug candidates. Ideally, a regimen against chronic HBV infection should completely eliminate all viral replicative intermediates, especially covalently closed circular DNA (cccDNA). For the past few decades, nucleic acid-based therapy has emerged as an attractive alternative that may result in complete clearance of HBV in infected patients. Several genetic anti-HBV strategies have been developed. The most studied approaches include the use of antisense oligonucleotides, ribozymes, RNA interference effectors and gene editing tools. This review will summarize recent developments and progress made in the use of gene therapy against HBV.
Collapse
|
8
|
Song H, Oh B, Choi M, Oh J, Lee M. Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy. J Drug Target 2015; 23:360-70. [PMID: 25572456 DOI: 10.3109/1061186x.2014.1000336] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Inhibition of microRNA-21 (miR-21) has been shown to promote apoptosis of cancer cells and to reduce tumor size in glioblastoma. However, efficient carriers for antisense-oligodeoxynucleotide (antisense-ODN) against miR-21 have not yet been developed. In this study, the R3V6 peptide (R3V6) was evaluated as a carrier of antisense-ODN. In a gel retardation assay, R3V6 formed a complex with an antisense-ODN. The serum stability assay showed that R3V6 protected it from nucleases more efficiently than polyethylenimine (PEI; 25 kDa, PEI25k). A Renilla luciferase gene with a 3'-untranslated region (3'-UTR) recognizable by miR-21 (psiCHECK2-miR-21-UTR) was constructed for the antisense-ODN assay. psiCHECK2-miR-21-UTR expressed less Renilla luciferase in the cells with a higher level of miR-21 due to the effect of miR-21. In an in vitro transfection assay, the R3V6 peptide delivered anti-miR-21 antisense-ODN into cells more efficiently than PEI (25 kDa, PEI25k) and lipofectamine. As a result, antisense-ODN/R3V6 complex inhibited miR-21 and increased Renilla luciferase expression more efficiently than antisense-ODN/PEI25k or antisense-ODN/Lipofectamine complexes in both C6 and A172 glioblastoma cells. Furthermore, the antisense-ODN/R3V6 complexes reduced the level of miR-21 and induced apoptosis of glioblastoma cells. These results suggest that the R3V6 peptide may be a useful carrier of antisense-ODN for glioblastoma gene therapy.
Collapse
Affiliation(s)
- Hojung Song
- BK21 Plus Future Biopharmaceutical Human Resources Training and Research Team, Department of Bioengineering, College of Engineering, Hanyang University , Seoul , Korea
| | | | | | | | | |
Collapse
|
9
|
|
10
|
Carbone M, Valentini F, Caminiti R, Petrinca AR, Donia D, Divizia M, Palleschi G. Are PEI-coated SWCNTs conjugated with hepatitis A virus? A chemical study with SEM,
Z
-potential, EDXD and RT-PCR. Biomed Mater 2010; 5:35001. [DOI: 10.1088/1748-6041/5/3/035001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
11
|
Namgung R, Kim J, Singha K, Kim CH, Kim WJ. Synergistic Effect of Low Cytotoxic Linear Polyethylenimine and Multiarm Polyethylene Glycol: Study of Physicochemical Properties and In Vitro Gene Transfection. Mol Pharm 2009; 6:1826-35. [DOI: 10.1021/mp900096u] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Ran Namgung
- Department of Chemistry, BK21 Program, Polymer Research Institute, Pohang University of Science and Technology, San 31, Hyoja-dong, Pohang 790-784, Korea, and Lab of Tissue Engineering, Korea Institute of Radiological and Medical Sciences, 215-4, Gongneung-Dong, Nowon-Gu, Seoul 139-706, Korea
| | - Jihoon Kim
- Department of Chemistry, BK21 Program, Polymer Research Institute, Pohang University of Science and Technology, San 31, Hyoja-dong, Pohang 790-784, Korea, and Lab of Tissue Engineering, Korea Institute of Radiological and Medical Sciences, 215-4, Gongneung-Dong, Nowon-Gu, Seoul 139-706, Korea
| | - Kaushik Singha
- Department of Chemistry, BK21 Program, Polymer Research Institute, Pohang University of Science and Technology, San 31, Hyoja-dong, Pohang 790-784, Korea, and Lab of Tissue Engineering, Korea Institute of Radiological and Medical Sciences, 215-4, Gongneung-Dong, Nowon-Gu, Seoul 139-706, Korea
| | - Chun Ho Kim
- Department of Chemistry, BK21 Program, Polymer Research Institute, Pohang University of Science and Technology, San 31, Hyoja-dong, Pohang 790-784, Korea, and Lab of Tissue Engineering, Korea Institute of Radiological and Medical Sciences, 215-4, Gongneung-Dong, Nowon-Gu, Seoul 139-706, Korea
| | - Won Jong Kim
- Department of Chemistry, BK21 Program, Polymer Research Institute, Pohang University of Science and Technology, San 31, Hyoja-dong, Pohang 790-784, Korea, and Lab of Tissue Engineering, Korea Institute of Radiological and Medical Sciences, 215-4, Gongneung-Dong, Nowon-Gu, Seoul 139-706, Korea
| |
Collapse
|
12
|
Park YG. [Inhibition of hepatitis B virus replication by RNA interference]. THE KOREAN JOURNAL OF HEPATOLOGY 2009; 15:1-6. [PMID: 19346780 DOI: 10.3350/kjhep.2009.15.1.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
|
13
|
Leaman DW. Recent progress in oligonucleotide therapeutics: antisense to aptamers. Expert Opin Drug Discov 2008; 3:997-1009. [DOI: 10.1517/17460441.3.9.997] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
14
|
Kim BK, Lim SO, Park YG. Requirement of the cyclic adenosine monophosphate response element-binding protein for hepatitis B virus replication. Hepatology 2008; 48:361-73. [PMID: 18615500 DOI: 10.1002/hep.22359] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
UNLABELLED The cyclic adenosine monophosphate-response element (CRE)-transcription factor complex participates in the regulation of viral gene expression and pathologic processes caused by various viruses. The hepatitis B virus (HBV) enhancer I directs liver-specific transcription of viral genes and contains a CRE sequence (HBV-CRE); however, whether the HBV-CRE and CRE-binding protein (CREB) are required for the HBV life cycle remains to be determined. This study was designed to investigate the role of CREB in HBV replication and gene expression. Sequence-comparison analysis of 984 HBVs reported worldwide showed that the HBV-CRE sequence is highly conserved, indicating the possibility that it plays an important role in the HBV life cycle. The binding of CREB to the HBV-CRE site was markedly inhibited by oligonucleotides containing HBV-CRE and consensus CRE sequences in vitro and in vivo. The HBV promoter activity was demonstrated to be dependent upon the transactivation activity of CREB. Treatment with CRE decoy oligonucleotides reduced HBV promoter activity, and this was reversed by CREB overexpression. The levels of viral transcripts, DNA, and antigens were remarkably decreased in response to the overexpression of CREB mutants or treatment with the CRE decoy oligonucleotides, whereas enhancing CREB activity increased the levels of viral transcripts. In addition, introduction of a three-base mutation into the HBV-CRE led to a marked reduction in HBV messenger RNA synthesis. CONCLUSION Taken together, our results demonstrate that both replication and gene expression of HBV require a functional CREB and HBV-CRE. We have also demonstrated that CRE decoy oligonucleotides and the overexpression of CREB mutants can effectively block the HBV life cycle, suggesting that interventions against CREB activity could provide a new avenue to treat HBV infection.
Collapse
Affiliation(s)
- Bo Kyung Kim
- Department of Biochemistry, Korea University College of Medicine, Seoul, Korea
| | | | | |
Collapse
|
15
|
Chang ML, Chen JC, Yeh CT, Chang MY, Liang CK, Chiu CT, Lin DY, Liaw YF. Gene Gun Bombardment with DNA-Coated Gold Particles Is a Potential Alternative to Hydrodynamics-Based Transfection for Delivering Genes into Superficial Hepatocytes. Hum Gene Ther 2008; 19:391-5. [DOI: 10.1089/hum.2007.152] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Affiliation(s)
- Ming-Ling Chang
- Liver Research Center and Department of Hepatogastroenterology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, and Chang Gung University, Taoyuan, Taiwan 33305
| | - Jeng-Chang Chen
- Department of Surgery, Chang Gung Children's Hospital, Taoyuan, Taiwan 33305
| | - Chau-Ting Yeh
- Liver Research Center and Department of Hepatogastroenterology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, and Chang Gung University, Taoyuan, Taiwan 33305
| | - Ming-Yu Chang
- Division of Pediatric Critical Care and Emergency Medicine, Chang Gung Children's Hospital, Taoyuan, Taiwan 33305
| | - Chun-Kai Liang
- Liver Research Center and Department of Hepatogastroenterology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, and Chang Gung University, Taoyuan, Taiwan 33305
| | - Cheng-Tang Chiu
- Liver Research Center and Department of Hepatogastroenterology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, and Chang Gung University, Taoyuan, Taiwan 33305
| | - Deng-Yn Lin
- Liver Research Center and Department of Hepatogastroenterology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, and Chang Gung University, Taoyuan, Taiwan 33305
| | - Yun-Fan Liaw
- Liver Research Center and Department of Hepatogastroenterology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, and Chang Gung University, Taoyuan, Taiwan 33305
| |
Collapse
|
16
|
Gonzalez-Aseguinolaza G, Crettaz J, Ochoa L, Otano I, Aldabe R, Paneda A. Gene therapy for viral hepatitis. Expert Opin Biol Ther 2006; 6:1263-78. [PMID: 17223736 DOI: 10.1517/14712598.6.12.1263] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Hepatitis B and C infections are two of the most prevalent viral diseases in the world. Existing therapies against chronic viral hepatitis are far from satisfactory due to low response rates, undesirable side effects and selection of resistant viral strains. Therefore, new therapeutic approaches are urgently needed. This review, after briefly summarising the in vitro and in vivo systems for the study of both diseases and the genetic vehicles commonly used for liver gene transfer, examines the existing status of gene therapy-based antiviral strategies that have been employed to prevent, eliminate or reduce viral infection. In particular, the authors focus on the results obtained in clinical trials and experimental clinically relevant animal models.
Collapse
MESH Headings
- Animals
- Disease Models, Animal
- Genetic Therapy/methods
- Genetic Therapy/trends
- Hepatitis B, Chronic/genetics
- Hepatitis B, Chronic/prevention & control
- Hepatitis C, Chronic/genetics
- Hepatitis C, Chronic/prevention & control
- Hepatitis, Viral, Animal/genetics
- Hepatitis, Viral, Animal/prevention & control
- Hepatitis, Viral, Human/genetics
- Hepatitis, Viral, Human/prevention & control
- Humans
Collapse
Affiliation(s)
- Gloria Gonzalez-Aseguinolaza
- University of Navarra, Division of Gene Therapy and Hepatology, Center for Applied Medical Research (CIMA), 31008 Pamplona, Spain.
| | | | | | | | | | | |
Collapse
|
17
|
Zhang Y, Rong Qi X, Gao Y, Wei L, Maitani Y, Nagai T. Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. J Control Release 2006; 117:281-90. [PMID: 17196291 DOI: 10.1016/j.jconrel.2006.11.006] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2006] [Revised: 09/04/2006] [Accepted: 11/09/2006] [Indexed: 11/23/2022]
Abstract
In order to deliver antisense oligonucleotides (asODN) into hepatocytes orientedly in the treatment of hepatitis B virus (HBV) infection, the liver-targeting cationic liposomes was developed as a gene carrier, which was co-modified with the ligand of the asialoglycoprotein receptor (ASGPR), beta-sitosterol-beta-d-glucoside (sito-G) and the nonionic surfactant, Brij 35. Flow cytometry (FCM) analysis and enzyme-linked immunosorbent assay (ELISA) showed that the asODN-encapsulating cationic liposomes exhibited high transfection efficiency and strong antigens inhibition effect in primary rat hepatocytes and HepG2.2.15 cells, respectively. With the help of several inhibitors acting on different steps during the targeting lipofection, the cellular uptake mechanisms of the co-modified liver-targeting cationic liposomes were investigated through antigens inhibition effect assay and confocal laser scanning microscopy (CLSM) analysis. The cellular uptake with high transfection efficiency seemed to involve both endocytosis and membrane fusion. The ligand sito-G was confirmed to be able to enhance ASGPR-mediated endocytosis, the nonionic surfactant Brij 35 seemed to be able to facilitate membrane fusion, and the co-modification resulted in the most efficient transfection but no enhanced cytotoxicity. These results suggested that the co-modified liver-targeting cationic liposomes would be a specific and effective carrier to transfer asODN into hepatocytes infected with HBV orientedly.
Collapse
Affiliation(s)
- Yuan Zhang
- School of Pharmaceutical Sciences, Peking University, Beijing, China
| | | | | | | | | | | |
Collapse
|
18
|
Zhang Z, Xi HL, Gong WB, Li WG, Yu M, Zeng Z, Xu XY. Retrovirus-mediated expression of dual-target antisense RNA in liver cells of transgenic mice and its influence on replication of hepatitis B virus. Shijie Huaren Xiaohua Zazhi 2006; 14:2551-2555. [DOI: 10.11569/wcjd.v14.i25.2551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To detect the expression of X and P region dual-target antisense RNA of hepatitis B virus (HBV) mediated by ratroviral vector in the liver cells of transgenic mice and its effect on the replication of HBV DNA.
METHODS: The recombinant retroviral vector plasmids expressing dual-target antisense RNA complementary to HBV X and P region were constructed and then injected into the transgenic mice. The experimental mice were divided into blank, pLXSN, pLXSN-asX, pLXSN-asP, pLXSN-asXP, and pLXSN-seXP group. The total RNA, extracted from the mice at the 8th wk, was reversely transcribed, and then the cDNA was amplified with polymerase chain reaction (PCR). Thereafter, agarose gel electrophoresis, sequencing analysis and fluorescent PCR were performed. The replication of HBV DNA was tested by fluorescence quantitative PCR.
RESULTS: The HBV dual-target antisense RNA was expressed in the liver cells of mice and with high efficiency. After 8 wk, the replications of HBV DNA (×105 copies/g) were 7.24 ± 1.62, 9.49 ± 3.34, 2.60 ± 1.13, 2.83 ± 1.67, 3.24 ± 0.45, 6.52 ± 1.53 in blank, pLXSN, pLXSN-asX, pLXSN-asP, pLXSN-asXP and pLXSN-seXP group. The levels of HBV DNA were significantly higher in single- or dual-target antisense RNA groups than those in other groups (P < 0.05). However, there were no marked differences between control groups as well as between single-target and dual-target group (P > 0.05).
CONCLUSION: The hepatitis B virus dual-target antisense RNA can be expressed in the liver cells of transgenic mice with high efficiency, and it can inhibit the replication of HBV DNA in mice liver. However, there is no significant difference between single-target and dual-target RNA.
Collapse
|
19
|
|
20
|
Zoulim F, Lucifora J. Hepatitis B virus drug resistance: mechanism and clinical implications for the prevention of treatment failure. Future Virol 2006. [DOI: 10.2217/17460794.1.3.361] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Hepatitis B virus (HBV) infection remains a major public health problem worldwide. Recently, the research efforts to identify new inhibitors enabled the development of antiviral agents to treat patients chronically infected by HBV. In clinical practice, the use of nucleoside analogs, which inhibit viral polymerase activity, induces suppression of viral replication accompanied by an improvement in biochemical and histological conditions in most patients. However, many clinical studies revealed the emergence of drug-resistant mutants during extended treatment. This review focuses on the mechanism of HBV drug-resistant mutant selection and on the clinical implications of HBV drug resistance for the prevention of treatment failure.
Collapse
Affiliation(s)
- Fabien Zoulim
- INSERM Unit 271, 151 cours Albert Thomas, 69003 Lyon, France
| | - Julie Lucifora
- INSERM Unit 271, 151 cours Albert Thomas, 69003 Lyon, France
| |
Collapse
|
21
|
Yamada Y, Kogure K, Nakamura Y, Inoue K, Akita H, Nagatsugi F, Sasaki S, Suhara T, Harashima H. Development of efficient packaging method of oligodeoxynucleotides by a condensed nano particle in lipid envelope structure. Biol Pharm Bull 2006; 28:1939-42. [PMID: 16204950 DOI: 10.1248/bpb.28.1939] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
An efficient delivery system is required if antisense oligodeoxynucleotides (ODN) are to be utilized for gene therapy. We report herein on the development of a novel ODN delivery system, ODN-encapsulated nano particles (ODN-ENP) using an efficient and simple packaging method. The ODN-ENP consists of a condensed ODN particle and a lipid envelope, which can be equipped with various functional devices for the efficient delivery of ODN with a small diameter (150 nm). The encapsulation efficiency and ODN recovery of ODN-ENP were significantly higher than those of other packaging methods, such as a stabilized antisense-lipid particles method or a freeze-thaw method. Furthermore, the time required for the preparation of the ODN-ENP was shorter than the other methods. The method developed in this study is a simple and efficient packaging method for ODN with a condensed nano particle in lipid-envelope structure.
Collapse
Affiliation(s)
- Yuma Yamada
- Graduate School of Pharmaceutical Sciences, Hokkaido University; Kita-12, Nishi-6, Sapporo 060-0812, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Ohmichi T, Kuwahara M, Sasaki N, Hasegawa M, Nishikata T, Sawai H, Sugimoto N. Nucleic Acid with Guanidinium Modification Exhibits Efficient Cellular Uptake. Angew Chem Int Ed Engl 2005; 44:6682-5. [PMID: 16172995 DOI: 10.1002/anie.200500904] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Tatsuo Ohmichi
- FIBER, Konan University and I.S.T. Corporation, 13-13-5 Ichiriyama, Otsu 520-2153, Japan
| | | | | | | | | | | | | |
Collapse
|
23
|
Ohmichi T, Kuwahara M, Sasaki N, Hasegawa M, Nishikata T, Sawai H, Sugimoto N. Nucleic Acid with Guanidinium Modification Exhibits Efficient Cellular Uptake. Angew Chem Int Ed Engl 2005. [DOI: 10.1002/ange.200500904] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
24
|
Prieto J, Qian C, Hernandez-Alcoceba R, Gonzalez-Aseguinolaza G, Mazzolini G, Sangro B, Kramer MG. Gene therapy of liver diseases. Expert Opin Biol Ther 2005; 4:1073-91. [PMID: 15268675 DOI: 10.1517/14712598.4.7.1073] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Many liver diseases lack satisfactory treatment and alternative therapeutic options are urgently needed. Gene therapy is a new mode of treatment for both inherited and acquired diseases, based on the transfer of genetic material to the tissues. Genes are incorporated into appropriate vectors in order to facilitate their entrance and function inside the target cells. Gene therapy vectors can be constructed on the basis of viral or non-viral molecular structures. Viral vectors are frequently used, due to their higher transduction efficiency. Both the type of vector and the expression cassette determine the duration, specificity and inducibility of gene expression. A considerable number of preclinical studies indicate that a great variety of liver diseases, including inherited metabolic defects, chronic viral hepatitis, liver cirrhosis and primary and metastatic liver cancer, are amenable to gene therapy. Gene transfer to the liver can also be used to convert this organ into a factory of secreted proteins needed to treat conditions that do not affect the liver itself. Clinical trials of gene therapy for the treatment of inherited diseases and liver cancer have been initiated but human gene therapy is still in its infancy. Recent progress in vector technology and imaging techniques, allowing in vivo assessment of gene expression, will facilitate the development of clinical applications of gene therapy.
Collapse
Affiliation(s)
- Jesus Prieto
- Department of Internal Medicine, Clinica Universitaria de Navarra, Avda. Pio XII 36, 31008 Pamplona, Spain
| | | | | | | | | | | | | |
Collapse
|
25
|
Springate CMK, Jackson JK, Gleave ME, Burt HM. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemother Pharmacol 2005; 56:239-47. [PMID: 15864591 DOI: 10.1007/s00280-004-0997-5] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2004] [Accepted: 11/29/2004] [Indexed: 10/25/2022]
Abstract
PURPOSE To develop and evaluate an injectable, controlled release delivery system for a phosphorothioate antisense oligonucleotide (ASO) based on complexed ASO:chitosan dispersed in a biodegradable polymeric paste for intratumoral treatment of solid tumors. METHODS Clusterin ASO was complexed with chitosan particles and incorporated into a paste based on a 60:40 blend of methoxy-poly(ethylene glycol) (MePEG) and triblock copolymer of poly(D: ,L: -lactic acid-co-caprolactone)-PEG-(D: ,L: -lactic acid-co-caprolactone). In vitro release profiles of clusterin ASO into phosphate-buffered saline at 37 degrees C were obtained under sink conditions and assayed by anionic exchange high-performance liquid chromatography. In vivo efficacy studies were carried out in human prostate PC-3 and LNCaP tumors grown subcutaneously in mice. Paste formulations of clusterin ASO with or without paclitaxel or docetaxel were injected intratumorally and tumor volumes and serum prostate specific antigen (PSA) levels were measured. RESULTS Controlled release of clusterin ASO was obtained over several weeks. The rate and extent of ASO release was proportional to the ratio of ASO to chitosan in the paste. Treatment of mice bearing PC-3 tumors with clusterin ASO plus paclitaxel or docetaxel paste had reduced mean tumor volume by greater than 50% at 4 weeks. Treatment of mice bearing LNCaP tumors with clusterin ASO plus paclitaxel reduced mean tumor volume and serum PSA level by more than 50% and 70%, respectively. CONCLUSIONS Complexation of clusterin ASO with chitosan and incorporation into polymeric paste with paclitaxel or docetaxel produced in vitro controlled release of the ASO and in vivo efficacy over 4 weeks following a single intratumoral injection in solid human prostate tumors in mice.
Collapse
MESH Headings
- Adenocarcinoma/drug therapy
- Adenocarcinoma/pathology
- Animals
- Antineoplastic Agents, Phytogenic/chemistry
- Antineoplastic Agents, Phytogenic/pharmacology
- Cell Line, Tumor/drug effects
- Chemistry, Pharmaceutical
- Chitosan/administration & dosage
- Chitosan/chemistry
- Clusterin
- Delayed-Action Preparations
- Docetaxel
- Drug Therapy, Combination
- Glycoproteins/administration & dosage
- Glycoproteins/chemistry
- Humans
- Injections, Intralesional
- Male
- Mice
- Mice, Inbred BALB C
- Molecular Chaperones/administration & dosage
- Molecular Chaperones/chemistry
- Neoplasm Transplantation
- Ointments
- Oligonucleotides, Antisense/administration & dosage
- Oligonucleotides, Antisense/chemistry
- Paclitaxel/administration & dosage
- Paclitaxel/chemistry
- Prostatic Neoplasms/drug therapy
- Prostatic Neoplasms/pathology
- Taxoids/administration & dosage
- Taxoids/chemistry
- Transplantation, Heterologous
- Xenograft Model Antitumor Assays
Collapse
|
26
|
Robaczewska M, Narayan R, Seigneres B, Schorr O, Thermet A, Podhajska AJ, Trepo C, Zoulim F, Nielsen PE, Cova L. Sequence-specific inhibition of duck hepatitis B virus reverse transcription by peptide nucleic acids (PNA). J Hepatol 2005; 42:180-7. [PMID: 15664242 DOI: 10.1016/j.jhep.2004.10.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2004] [Revised: 09/17/2004] [Accepted: 10/04/2004] [Indexed: 01/02/2023]
Abstract
BACKGROUND/AIMS Peptide nucleic acids (PNAs) appear as promising new antisense agents, that have not yet been examined as hepatitis B virus (HBV) inhibitors. Our aim was to study the ability of PNAs targeting the duck HBV (DHBV) encapsidation signal epsilon to inhibit reverse transcription (RT) and to compare their efficacy with phosphorothioate oligodeoxynucleotides (S-ODNs). METHODS The effect of two partly overlapping PNAs targeting epsilon and of analogous S-ODNs was tested in cell-free transcription and translation system for DHBV RT expression. In addition their antiviral effect was investigated in primary duck hepatocytes (PDH). RESULTS Both PNAs reproducibly inhibited DHBV RT in a dose-dependent manner with IC(50) of 10nM, whereas up to 600-fold higher concentration of S-ODNs was required for similar inhibition. The PNA targeting the bulge and upper stem of epsilon appeared as more efficient RT inhibitor than the PNA targeting only the bulge. Importantly, the inhibition was highly sequence-specific since double-mismatched PNA had no effect on the RT reaction. Moreover, in PDH the PNA coupled to Arg(7) cationic delivery peptide decreased DHBV replication. CONCLUSIONS We provide the first evidence that PNAs targeting the bulge and upper stem of epsilon can efficiently and in a sequence-specific manner inhibit DHBV RT.
Collapse
|
27
|
Sarkar T, Conwell CC, Harvey LC, Santai CT, Hud NV. Condensation of oligonucleotides assembled into nicked and gapped duplexes: potential structures for oligonucleotide delivery. Nucleic Acids Res 2005; 33:143-51. [PMID: 15640449 PMCID: PMC546144 DOI: 10.1093/nar/gki156] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
The condensation of nucleic acids into well-defined particles is an integral part of several approaches to artificial cellular delivery. Improvements in the efficiency of nucleic acid delivery in vivo are important for the development of DNA- and RNA-based therapeutics. Presently, most efforts to improve the condensation and delivery of nucleic acids have focused on the synthesis of novel condensing agents. However, short oligonucleotides are not as easy to condense into well-defined particles as gene-length DNA polymers and present particular challenges for discrete particle formation. We describe a novel strategy for improving the condensation and packaging of oligonucleotides that is based on the self-organization of half-sliding complementary oligonucleotides into long duplexes (ca. 2 kb). These non-covalent assemblies possess single-stranded nicks or single-stranded gaps at regular intervals along the duplex backbones. The condensation behavior of nicked- and gapped-DNA duplexes was investigated using several cationic condensing agents. Transmission electron microscopy and light-scattering studies reveal that these DNA duplexes condense much more readily than short duplex oligonucleotides (i.e. 21 bp), and more easily than a 3 kb plasmid DNA. The polymeric condensing agents, poly-l-lysine and polyethylenimine, form condensates with nicked- and gapped-DNA that are significantly smaller than condensates formed by the 3 kb plasmid DNA. These results demonstrate the ability for DNA structure and topology to alter nucleic acid condensation and suggest the potential for the use of this form of DNA in the design of vectors for oligonucleotide and gene delivery. The results presented here also provide new insights into the role of DNA flexibility in condensate formation.
Collapse
Affiliation(s)
| | | | - Lilia C. Harvey
- Department of Chemistry, Agnes Scott CollegeDecatur, GA 30030, USA
| | | | - Nicholas V. Hud
- To whom correspondence should be addressed. Tel: +1 404 385 1162; Fax: +1 404 894 2295;
| |
Collapse
|
28
|
Yuan J, Cheung PKM, Zhang H, Chau D, Yanagawa B, Cheung C, Luo H, Wang Y, Suarez A, McManus BM, Yang D. A phosphorothioate antisense oligodeoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts. J Transl Med 2004; 84:703-14. [PMID: 15094712 DOI: 10.1038/labinvest.3700083] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Antisense oligodeoxynucleotides (AS-ODNs) are promising therapeutic agents for the treatment of virus-induced diseases. We previously reported that coxsackievirus B3 (CVB3) infectivity could be inhibited effectively in HeLa cells by phosphorothioate AS-ODNs complementary to different regions of the 5' and 3' untranslated regions of CVB3 RNA. The most effective target is the proximal terminus of the 3' untranslated region. To further investigate the potential antiviral role of the AS-ODN targeting this site in cardiomyocytes (HL-1 cell line), corresponding AS-ODN (AS-7) was transfected into the HL-1 cells and followed by CVB3 infection. Analyses by RT-PCR, Western blotting and plaque assay demonstrated that AS-7 strongly inhibits viral RNA and viral protein synthesis as compared to scrambled AS-ODNs. The percent inhibitions of viral RNA transcription and capsid protein VP1 synthesis were 87.6 and 40.1, respectively. Moreover, AS-7 could inhibit ongoing CVB3 infection when it was given after virus infection. The antiviral activity was further evaluated in a CVB3 myocarditis mouse model. Adolescent A/J mice were intravenously administrated with AS-7 or scrambled AS-ODNs prior to and after CVB3 infection. Following a 4-day therapy, the myocardium CVB3 RNA replication decreased by 68% and the viral titers decreased by 0.5 log(10) in the AS-7-treated group as compared to the group treated with the scrambled AS-ODNs as determined by RT-PCR, in situ hybridization and viral plaque assay. Taken together, our results demonstrated a great potential for AS-7 to be further developed into an effective treatment towards viral myocarditis as well as other diseases caused by CVB3 infection.
Collapse
Affiliation(s)
- Ji Yuan
- Department of Pathology and Laboratory Medicine, The James Hogg iCAPTURE Centre, University of British Columbia-St Paul's Hospital, Vancouver, British Columbia, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Affiliation(s)
- Christian Trepo
- Department of Hepatology Hotel-Dieu Hospital, 1 Place de l'Hopital, 69288 Lyon Cedex 02, France.
| | | | | |
Collapse
|
30
|
Wen SY, Wang XH, Lin L, Guan W, Wang SQ. Preparation and property analysis of a hepatocyte targeting pH-sensitive liposome. World J Gastroenterol 2004; 10:244-9. [PMID: 14716832 PMCID: PMC4717013 DOI: 10.3748/wjg.v10.i2.244] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
AIM: To develop a hepatocyte targeting pH-sensitive liposome for drug delivery based on active targeting technology mediated by asialoglycoprotein receptors.
METHODS: Four types of targeting molecules with galactose residue were synthesized and mixed with pH-sensitive lipids DC-chol/DOPE to prepare liposome with integrated property of hepatocyte specificity and pH sensitivity. Liposome 18-gal was selected with the best transfection activity through cellular uptake experiment. Property analysis was made through experiments of competitive inhibition of receptors, red blood cell hemolysis, in vitro cytotoxicity test by MTS assay and mediation of inhibitory effects of antisense phosphorothioate ODN on gene expression, etc.
RESULTS: Liposome 18-gal had the desired properties of hepatocyte specificity, pH sensitivity, low cytotoxicity, and high transfection efficiency.
CONCLUSION: Liposome 18-gal can be further developed as a potential hepatocyte- targeting delivery system.
Collapse
Affiliation(s)
- Si-Yuan Wen
- Beijing Institute of Radiation Medicine, Beijing 100850, China
| | | | | | | | | |
Collapse
|
31
|
Abstract
Current treatment modalities available for hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are not efficient. The enormous disease burden caused by these two infections makes the development of novel therapies critical. For HCV, the development of an effective vaccine is urgent in view of the escalating number of infected individuals. Molecular therapies for HBV and HCV infection can be directed at reducing viral load by interfering with the life cycle of the viruses or at generating immune response against viral epitopes. The antiviral approaches consist of the delivery or expression of antisense RNAs, ribozymes or dominant negative proteins. Viral biology can be interrupted by attacking various potential targets within the two viruses. DNA-based vaccination strategies are being explored for both prevention and treatment of these diseases. Both non-viral and recombinant viral vectors are being developed for safe, effective and long-term gene transfer to the liver. Although no "ideal" vector is available at this time, the ingenuity of numerous investigators is leading to the improvement of the vector systems, promising successful application of gene therapy to the prevention and treatment of viral hepatitis in the foreseeable future.
Collapse
Affiliation(s)
- Chandan Guha
- Department of Radiation Oncology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
| | | | | | | | | | | |
Collapse
|
32
|
Kan QC, Yu ZJ, Lei YC, Hao LJ, Yang DL. Lethiferous effects of a recombinant vector carrying thymidine kinase suicide gene on 2.2.15 cells via a self-modulating mechanism. World J Gastroenterol 2003; 9:2216-20. [PMID: 14562381 PMCID: PMC4656466 DOI: 10.3748/wjg.v9.i10.2216] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To determine the lethiferous effects of a recombinant vector carrying thymidine kinase (TK) suicide gene on 2.2.15 cells and the possible self-modulating mechanism.
METHODS: A self-modulated expressive plasmid pcDNA3-SCITK was constructed by inserting the fragments carrying hepatitis B virus antisense-S (HBV-anti-S) gene, hepatitis C virus core (HCV-C) gene, internal ribosome entry site (IRES) element of HCV and TK gene into the eukaryotic vector pcDNA3, in which the expression of TK suicide gene was controlled by the HBV S gene transcription. 2.2.15 cells that carry the full HBV genome and stably express series of HBV antigen were transfected with pcDNA3-SCITK or vector pcDNA3-SCI which was used as the mock plasmid. The HepG2 cells transfected with pcDNA3-SCITK were functioned as the negative control. All the transfected cells were incubated in DMEM medium supplemented with 10 μg/mL. of ganciclovir (GCV). The HBsAg levels in the supernatant of cell culture were detected by ELISA on the 1st, 3rd and 6th day post-transfection. Meanwhile, the morphology of tranfected cells was recorded by the photograph and the survival cell ratio was assessed by the trypan blue exclusion test on the 6th day post-transfection.
RESULTS: The structural accuracy of pcDNA3-SCITK was confirmed by restriction endonuclease digestion, PCR with specific primers and DNA sequencing. The HBsAg levels in the supernatant of transfected 2.2.15 cell culture were significantly decreased on the 6th day post-transfection as compared with that of the mock control (P < 0.05). The lethiferous effect of pcDNA3-SCITK expression on 2.2.15 cells was initially noted on the 3rd day after transfection and aggravated on the 6th day post transfection, in which the majority of transfected 2.2.15 cells were observed shrunken, round in shape and even dead. With assessment by the trypan blue exclusion test, the survival cell ratio on the 6th day post transfection was 95% in the negative control and only 11% in the experimental group.
CONCLUSION: The results indicate that suicide gene expression of pcDNA3-SCITK can only respond to HBV-S gene transcription, which may be potentially useful in the treatment of HBV infection and its related liver malignancies.
Collapse
Affiliation(s)
- Quan-Cheng Kan
- Division of Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
| | | | | | | | | |
Collapse
|
33
|
Zheng SJ, Zhong S, Zhang JJ, Chen F, Ren H, Deng CL. Distribution and anti-HBV effects of antisense oligodeoxynu-cleotides conjugated to galactosylated poly-L-lysine. World J Gastroenterol 2003; 9:1251-5. [PMID: 12800234 PMCID: PMC4611794 DOI: 10.3748/wjg.v9.i6.1251] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To describe distribution of the phosphorothioated antisense oligodeoxynucleotides (PS-asODNs) conjugated to galactosylated poly-L-lysine (Gal-PLL) in mice, and to observe their effects on expression of HBV gene in the 2.2.15 cells and transgenic mice.
METHODS: According to the result of direct sequencing of PCR amplified products, a 16 mer phosphorothioate analogue of the antisense oligodeoxynucleotides (PS-asODNs) directed against the HBV U5-like region was conjugated to the hepatotropic Gal-PLL molecules. Its distribution was demonstrated using asODNs labeled with 32P at the 5’ terminus with a T4-polynucleotide Kinase. Its inhibition effect on HBV expression was observed in the transfected 2.2.15 cells and transgenic mice.
RESULTS: The Gal-PLL and asODNs could form stable complex at a molar ratio of 2:1. As shown in the HBV-transfected 2.2.15 cells, the inhibition effects of asODNs alone and asODNs conjugated to Gal-PLL, at 10 μmol/L for both, on HBsAg and HBeAg production were different, the former being 70% and 58%, respectively, and the latter being 96% and 82%, respectively. A more pronounced reduction was also observed in viral DNA load in the culture supernatant for the test with Gal-PLL-asODNs. Among many mouse organs, livers retained more asODNs molecules after administration. The preferential concentration in liver was found to be 52.14% for Gal-PLL-asODNs, as high as 2.38-fold of that for asODNs (21.9%). Both elements decreased gradually in liver, with 2.9% of the former, 5.99% of the latter retained 24 h after the administration. The injection interval, therefore, was recommended to be 24 h. In the transgenic mice, serum HBsAg decreased significantly (P < 0.01) at the 12th day after administrating Gal-PLL- asODNs, the serum HBV DNA turned negative in 4 of the 6 mice.
CONCLUSION: Antisense oligodeoxynucleotides conjugated to Gal-PLL can be concentrated in liver and intaked by hepatocytic cells. This may result in specific inhibition of expression and replication of HBV in vitro and in vivo.
Collapse
Affiliation(s)
- Su-Jun Zheng
- Institute of Viral Hepatitis, Chongqing University of Medical Sciences, Chongqing 400016, China
| | | | | | | | | | | |
Collapse
|
34
|
Huang CH, Ou-Yang L, Ma HH, Tang ZH, Li G, Yao JL. Construction of replication-deficient recombinant adenoviral vector carrying HBV S and C region gene by homologous recombination in bacteria and its expression in vitro. Shijie Huaren Xiaohua Zazhi 2003; 11:438-441. [DOI: 10.11569/wcjd.v11.i4.438] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM To construct recombinant adenoviral vector carrying HBV S and C region gene by homologous recombination in bacteria and to detect its expression in vitro.
METHODS HBV pre-S2/S genes and pre-C/C genes were amplified by PCR and were cloned to adenoviral shuttle plasmid pAdTrack-CMV, respectively. Then the resultant pAd Track-CMV-HBs or pAdTrack-CMV-HBe was cotransfected into BJ5183 bacteria with the plasmid pAdeasy-1. The adenoviral plasmid carrying HBV S and C gene (pAd-HBs and pAd-HBe) was generated with homologous recombination in bacteria and the adenoviruses were produced in 293 cells. Both 293 and Vero cells were infected with adenoviruses and the expression of HBsAg and HBeAg was detected by RT-PCR and ELISA in vitro.
RESULTS The titer of Ad-HBs and Ad-HBe adenoviruses was up to 5×1012 pfu/L after proliferation in 293 cells. HBsAg and HBeAg were expressed efficiently in 293 and Vero cells after infection.
CONCLUSION The recombinant adenoviruses expressing HBsAg or HBeAg were constructed successfully and can be used further in gene therapy of HBV.
Collapse
Affiliation(s)
- Cheng-Hui Huang
- Department of Infectious Diseases, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, Guangdong Province, China
| | - Ling Ou-Yang
- Shenzhen Baoan Blood Center, Shenzhen 518101, Guangdong Province, China
| | - Hui-Hui Ma
- Department of Infectious Diseases, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, Guangdong Province, China
| | - Zheng-Hao Tang
- Department of Infectious Diseases, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, Guangdong Province, China
| | - Gong Li
- Department of Infectious Diseases, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, Guangdong Province, China
| | - Ji-Lu Yao
- Department of Infectious Diseases, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, Guangdong Province, China
| |
Collapse
|
35
|
Abstract
Liver transplantation has become a well-recognized therapy for hepatic failure resulting from acute or chronic liver disease. It also plays a role in the treatment of certain inborn errors of metabolism that do not directly injure the liver. In fact, the liver maintains a central role in many inherited and acquired genetic disorders. There has been a considerable effort to develop new and more effective gene therapy approaches, in part, to overcome the need for transplantation as well as the shortage of donor livers. Traditional gene therapy involves the delivery of a piece of DNA to replace the faulty gene. More recently, there has been a growing interest in the use of gene repair to correct certain genetic defects. In fact, targeted gene repair has many advantages over conventional replacement strategies. In this review, we will describe a variety of viral and nonviral strategies that are now available to the liver. The ever-growing list includes viral vectors, antisense and ribozyme technology, and the Sleeping Beauty transposon system. In addition, targeted gene repair with RNA/DNA oligonucleotides, small-fragment homologous replacement, and triplex-forming and single-stranded oligonucleotides is a long-awaited and potentially exciting approach. Although each method uses different mechanisms for gene repair and therapy, they all share a basic requirement for the efficient delivery of DNA.
Collapse
Affiliation(s)
- Betsy T Kren
- Department of Medicine, University of Minnesota School of Medicine, Minneapolis, MN 55455, USA
| | | | | | | |
Collapse
|
36
|
Dias N, Stein CA. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 2002; 54:263-9. [PMID: 12445555 DOI: 10.1016/s0939-6411(02)00060-7] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Antisense oligonucleotides have been widely used to specifically and selectively downregulate gene expression at the messenger RNA level. Even though oligonucleotides are commonly used in laboratories and clinical trials, they can induce non-specific effects that can lead to misinterpretation of experimentally-derived results. This review summarizes precautions one should take when using oligonucleotides. In addition, the role of one oligonucleotide, G3139, which is targeted to the coding region of bcl-2 messenger RNA, in inhibiting tumor progression in vitro and in clinical trials, is described.
Collapse
|
37
|
Abstract
The development of molecular conjugates as components of Protein/DNA polyplexes has resulted in the creation of a simple, non-virus vector for the targeted delivery of nucleic acids into specific cell types. This vector has many of the positive attributes of viruses, on without the limitations that continue to plague recombinant viruses. The simplicity of this vector allows for quick analysis of nucleic acids, expression vectors, and therapeutic genes in vitro and potentially in vivo, because the time that would be involved in the generation of recombinant viral vectors is not present. Essentially, the development of this delivery vector has resulted in the creation of a "synthetic virus" that has the capability of targeted delivery without the negative attributes of viruses.
Collapse
Affiliation(s)
- Richard J Cristiano
- Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 427, Houston, TX 77030, USA.
| |
Collapse
|